These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Management of cutaneous melanoma. Tsao H; Atkins MB; Sober AJ N Engl J Med; 2004 Sep; 351(10):998-1012. PubMed ID: 15342808 [No Abstract] [Full Text] [Related]
11. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b. Moschos SJ; Kirkwood JM; Konstantinopoulos PA J Clin Oncol; 2004 Jan; 22(1):11-4. PubMed ID: 14665613 [No Abstract] [Full Text] [Related]
12. Lipoatrophy associated with interferon alfa adjuvant therapy for melanoma. Vallés L; González M; Polo I; Enguita AB; Vanaclocha F; Ortiz-Romero PL Arch Dermatol; 2009 Jan; 145(1):98-9. PubMed ID: 19153363 [No Abstract] [Full Text] [Related]
13. [Feasability and tolerance of adjuvant treatment of melanoma with immunotherapy according to Kirkwood protocol]. Uwer L; Martin S; Geoffrois L; Schmutz JL Ann Dermatol Venereol; 2005 Jan; 132(1):50-1. PubMed ID: 15746611 [No Abstract] [Full Text] [Related]
14. Grand mal seizure induced by interferon-alpha-2b. Kors C; Milling A; Hofmann M; Sterry W; Trefzer U J Eur Acad Dermatol Venereol; 2006 Apr; 20(4):473-4. PubMed ID: 16643159 [No Abstract] [Full Text] [Related]
15. The role of adjuvant interferon in high risk melanoma patients. Dermatol Surg; 2000 Jun; 26(6):607-8. PubMed ID: 10848951 [No Abstract] [Full Text] [Related]